retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports GLP-3 Dosing Protocol UAE: How

Consequently, observed reductions in cancer incidenceparticularly for colorectal and liver cancers should be interpreted with caution and cannot be assumed to reflect long-term cancer prevention

Visit www.ifebp.org/CanadaGLP2025 for more information and to view the full survey report.

I designed this schematic on BioRender to visualize what I think is happening to my patients

A brief overview of the key findings is provided below

The GLP-1R interacts with structurally related peptide hormone ligands, such as glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), parathyroid hormone, etc